CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Talius Selected for 2025/26 MedTech Global Accelerator

From Talius

December 31, 2025

Talius Selected for 2025/26 MedTech Global Accelerator

Talius Selected for 2025/26 MedTech Global Accelerator
Talius has been selected for the 2025/26 MedTech Global Accelerator, delivered by Brisbane Economic Development Agency in partnership with Life Science Nation. The six-month program supports high-potential medical and digital health ventures and culminates at J.P. Morgan Healthcare Week in San Francisco in January 2026. Talius will use the accelerator to engage global investors and partners for its patient-centred health platform.

View original article on talius.com.au

Most Recent

TikTok Bans Musk Film Account, Citing Politics

Move comes just as Alex Gibney doc film expands to nearly 500 screens. Distributor Bleecker Street says it is appealing.

Oct 17, 2026

Software’s new consolidator gets big vote of confidence from Berkshire

Less than four months into life as a public company, Bending Spoons got a big vote of confidence this week from Berkshire Hathaway.

Oct 17, 2026

Zelenskyy Says Starlink Limits on Ukraine Military Are a 'Planned Operation'

Restrictions on Ukraine's military use of SpaceX's Starlink system appear to be deliberate and not the result …

Oct 17, 2026

Japan's Kioxia sheds two-thirds of peak market value as China chip rivals emerge

TOKYO — Japanese memory chip maker Kioxia Holdings' market value has shrunk to one-third of the peak it reached just four months ago …

Oct 16, 2026

Similar Posts

Talius Accelerates Global Growth with Strategic UK & Europe Appointment

Talius Group has appointed Alexandra Michelis as UK & Europe Regional Manager to drive international expansion across regulated healthcare markets.

Dec 31, 2025

Esther and Anne Wojcicki back new healthcare accelerator, fund

Mary Minno launches early-stage startup accelerator program, Treehub, and an early-stage firm, AI Health Fund, aimed at backing startups working at the intersection of healthcare and AI.

Apr 22, 2026

Leantime selected for the RIoT Accelerator Program Cohort XVI

Leantime announced it was one of seven companies selected for RIoT’s Fall XVI accelerator cohort.

Sep 1, 2023

StartUp Health Adds 6 Digital Health Startups to its Portfolio

StartUp Health named AlemHealth among six digital health companies added to its global portfolio, bringing the total to 90. The article describes cofounders Aschkan Abdul-Malek and Sajjad Kamal's integrated telemedicine solution that links hospitals in developing countries to a global provider network.

Feb 2, 2015